Cornerstone Capital’s NovoCure NVCR Stock Holding History

Cornerstone Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,045	Closed	-$232K	–	92
2021 Q2	$232K	Buy	+1,045	New	+$203K	0.03%	84

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cornerstone Capital's NVCR Position: Q3 2021 in Review

Cornerstone Capital sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,045 shares — an estimated $232K sold.

Cornerstone Capital first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $232K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

Cornerstone Capital reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
Cornerstone Capital sold 1,045 NovoCure shares in Q3 2021, an estimated $232K.
Cornerstone Capital first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
Cornerstone Capital's NovoCure position peaked at $232K in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Cornerstone Capital's 13F filing for Q3 2021, filed 9 Nov 2021.